BUB
BIO icon

BBVA USA Bancshares’s Bio-Rad Laboratories Class A BIO Stock Holding History

BBVA USA Bancshares’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$2.24M Buy
3,926
+24
+0.6% +$14.2K 0.11% 184
2020
Q4 		$2.27M Sell
3,902
-13
-0.3% -$7.4K 0.12% 166
2020
Q3 		$1.99M Buy
3,915
+38
+1% +$19.2K 0.11% 164
2020
Q2 		$1.75M Buy
3,877
+31
+0.8% +$13.7K 0.1% 172
2020
Q1 		$1.35M Buy
3,846
+311
+9% +$114K 0.1% 185
2019
Q4 		$1.31M Buy
+3,535
New +$1.25M 0.07% 219
2019
Q3 		– Sell
-3,630
Closed -$1.13M – 387
2019
Q2 		$1.13M Sell
3,630
-46
-1% -$13.8K 0.07% 235
2019
Q1 		$1.12M Sell
3,676
-385
-9% -$104K 0.07% 225
2018
Q4 		$943K Sell
4,061
-60
-1% -$16.1K 0.07% 233
2018
Q3 		$1.29M Sell
4,121
-45
-1% -$14K 0.08% 228
2018
Q2 		$1.2M Sell
4,166
-50
-1% -$13.8K 0.08% 228
2018
Q1 		$1.05M Buy
4,216
+36
+0.9% +$9.17K 0.07% 251
2017
Q4 		$998K Sell
4,180
-198
-5% -$48K 0.06% 267
2017
Q3 		$972K Sell
4,378
-63
-1% -$14.2K 0.06% 269
2017
Q2 		$1M Sell
4,441
-96
-2% -$20.9K 0.07% 258
2017
Q1 		$905K Buy
4,537
+178
+4% +$34.3K 0.06% 281
2016
Q4 		$795K Buy
4,359
+42
+1% +$7.16K 0.06% 291
2016
Q3 		$707K Buy
4,317
+86
+2% +$13.1K 0.05% 297
2016
Q2 		$605K Sell
4,231
-191
-4% -$27.2K 0.05% 315
2016
Q1 		$604K Buy
4,422
+625
+16% +$82K 0.05% 327
2015
Q4 		$526K Sell
3,797
-45
-1% -$6.24K 0.04% 333
2015
Q3 		$516K Buy
3,842
+299
+8% +$43K 0.04% 314
2015
Q2 		$534K Buy
3,543
+309
+10% +$44.2K 0.03% 338
2015
Q1 		$437K Sell
3,234
-62
-2% -$7.68K 0.02% 420
2014
Q4 		$397K Buy
3,296
+187
+6% +$21.5K 0.02% 435
2014
Q3 		$352K Sell
3,109
-70
-2% -$8.29K 0.02% 446
2014
Q2 		$381K Buy
3,179
+149
+5% +$18.2K 0.02% 435
2014
Q1 		$388K Buy
3,030
+157
+5% +$20.1K 0.02% 418
2013
Q4 		$355K Buy
2,873
+156
+6% +$19K 0.02% 428
2013
Q3 		$319K Buy
2,717
+256
+10% +$30.2K 0.02% 420
2013
Q2 		$276K Buy
+2,461
New +$289K 0.01% 406

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BBVA USA Bancshares's BIO Position: Q1 2021 in Review

BBVA USA Bancshares increased its Bio-Rad Laboratories Class A (BIO) stake by 0.62% in Q1 2021, buying an estimated $14.2K and bringing the position to 3,926 shares worth $2.24M. The position accounts for 0.11% of the portfolio, ranked #184.

BBVA USA Bancshares first reported a position in BIO in Q2 2013 and has held it in 31 quarters since. The position peaked at $2.27M in Q4 2020. 492 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

  • BBVA USA Bancshares held 3,926 shares of Bio-Rad Laboratories Class A worth $2.24M as of Q1 2021.
  • BBVA USA Bancshares bought 24 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $14.2K.
  • Bio-Rad Laboratories Class A made up 0.11% of BBVA USA Bancshares's portfolio in Q1 2021, its #184 holding.
  • BBVA USA Bancshares first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 31 quarters since.
  • BBVA USA Bancshares's Bio-Rad Laboratories Class A position peaked at $2.27M in Q4 2020.
  • 492 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on BBVA USA Bancshares's 13F filing for Q1 2021, filed 23 Apr 2021.